TB-500 Side Effects: What the Research Shows — Safety Data Indexed
TB-500 Side Effects: What the Research Shows
TB-500 side effects data in the peer-reviewed literature comes from three sources: preclinical animal studies, Phase I human safety trials of full-length thymosin beta-4, and theoretical safety analyses. No controlled human adverse-event data for the TB-500 heptapeptide fragment (Ac-LKKTETQ) specifically exists in indexed literature as of 2026.
This page indexes what has been observed and what remains uncharacterized. It does not assess risk for human use. TB-500 is not FDA-approved and is classified as a research compound.
Safety Profile of TB-500 in Animal Studies
Preclinical animal studies have generally reported favorable tolerability across the dose ranges studied:
Rodent wound healing (Malinda et al., 1999): Topical and intraperitoneal thymosin beta-4 was administered to rats across multiple experiments without reported systemic toxicity [3].
Dystrophin-deficient mouse model (Spurney et al., 2010): 150 µg twice weekly for 6 months — a chronic administration protocol. No severe adverse events were reported; the primary finding was increased regenerating muscle fibers without improvement in overall strength or cardiac function in that specific model [9].
Corneal alkali burn (Sosne et al., 2002): Topical Tβ4 was well tolerated in mice across a 7-day observation window; no adverse ocular effects were reported [11].
Stroke and TBI models (Morris et al., 2014; Xiong et al., 2012): Systemic injection across 2–12 mg/kg dose ranges in rats. No treatment-related mortality or severe adverse events described [17][18].
Rodent models provide limited predictive power for human adverse-event profiles. Sample sizes in these studies are typically small (n = 5–15 per group).
Reported Adverse Effects in TB-500 Research
Published human Phase I data is for full-length thymosin beta-4, not the TB-500 fragment:
Ruff et al. (2010): Randomized, placebo-controlled Phase I of IV synthetic Tβ4 in 36 healthy volunteers. Doses from 42 to 1260 mg in single and 14-day repeated dosing regimens. Adverse events were infrequent and rated mild-to-moderate; no dose-limiting toxicities or serious adverse events were observed. Pharmacokinetics were dose-proportional [13].
Wang et al. (2021): Phase I of recombinant human Tβ4 (NL005) in 40 healthy Chinese volunteers. Single doses 0.05–25.0 µg/kg IV; multiple daily doses at 0.5, 2.0, 5.0 µg/kg for 10 days. Adverse events mild-to-moderate; no dose-limiting toxicities or serious adverse events. No accumulation [21].
Neither trial reported allergic reactions, injection-site necrosis, or clinically significant hematological or biochemical abnormalities at studied doses. The animal literature has noted transient fatigue and mild lethargy at higher doses in some rodent models — specific study citations are not available for this observation in the indexed literature; it is a commonly reported preclinical peptide finding.
Immunological Considerations in TB-500 Research
As a synthetic peptide, TB-500 could theoretically elicit immune responses including injection-site inflammation or systemic hypersensitivity reactions. The LKKTETQ sequence is a fragment of an endogenous human protein — the same seven residues are present in native thymosin beta-4 — which reduces (but does not eliminate) the likelihood of a de novo adaptive immune response.
The published Phase I human trials of full-length Tβ4 did not report allergic reactions or antibody formation at the doses studied [13][21]. No controlled immunological characterization of the shorter TB-500 heptapeptide fragment in human subjects has been published.
Thymosin beta-4 modulates immune cell trafficking — it promotes macrophage migration, affects neutrophil infiltration [11], and influences the NF-κB inflammatory axis [6]. Whether administered TB-500 at research-compound doses perturbs systemic immune function is not characterized in published literature.
Long-Term Safety Considerations for TB-500 Research
Long-term human safety data for TB-500 does not exist. The longest animal study in the literature is the 6-month mdx mouse protocol at 150 µg twice weekly — which reported no severe adverse events [9]. Human Phase I studies ran a maximum of 14 days for full-length Tβ4 [13].
Thymosin beta-4 promotes cell migration, angiogenesis, and survival signaling pathways. Tβ4 is elevated in several human tumors and has been proposed as a potential oncological biomarker in some contexts. Whether exogenous administration at research-compound doses meaningfully perturbs oncological risk is uncharacterized — the animal studies were not designed to detect long-term oncological endpoints.
The controversies in the literature include:
- The theoretical concern that pro-migration and pro-survival signaling could facilitate tumor cell behavior — uncharacterized at research-compound doses.
- WADA's classification of TB-500 as a growth factor under S2.3, reflecting regulatory judgment that it provides performance-enhancing effects — which implies meaningful physiological activity at administered doses [2].
- The absence of peer-reviewed long-term safety data in any species beyond 6 months.
These considerations are relevant to research design and protocol review, not to self-administration.